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In response to virus infection, cells can alter pro-
tein expression to modify cellular functions and limit
viral replication. To examine host protein expres-
sion during infection with human cytomegalovirus
(HCMV), an enveloped DNA virus, we performed a
semiquantitative, temporal analysis of the cell sur-
face proteome in infected fibroblasts. We deter-
mined that resident low density lipoprotein related
receptor 1 (LRP1), a plasma membrane receptor
that regulates lipid metabolism, is elevated early
after HCMV infection, resulting in decreased intra-
cellular cholesterol. siRNA knockdown or antibody-
mediated inhibition of LRP1 increased intracellular
cholesterol and concomitantly increased the infec-
tious virus yield. Virions produced under these con-
ditions contained elevated cholesterol, resulting in
increased infectivity. Depleting cholesterol from
virions reduced their infectivity by blocking fusion
of the virion envelope with the cell membrane.
Thus, LRP1 restricts HCMV infectivity by controlling
the availability of cholesterol for the virion envelope,
and increased LRP1 expression is likely a defense
response to infection.
INTRODUCTION
Human cytomegalovirus (HCMV) is a b-herpesvirus that infects
more than 60% of adults, resulting in establishment of life-long
viral latency (Mocarski et al., 2007). It is a major cause of birth
defects, where congenital infection causes disabilities such as
hearing loss and retardation (Pereira and Maidji, 2008). HCMV
is also an opportunistic agent in immunosuppressed individuals
(Britt, 2008), and it might contribute to cardiovascular disease
(Streblow et al., 2008), cancer (Soroceanu and Cobbs, 2011),
and immune senescence (Moss, 2010).
Like all viruses, HCMV relies on numerous host cell functions
for its replication. As a consequence, it has evolved mechanisms
to hijack aspects of cell machinery in order to replicate efficiently.
HCMV modulates diverse classes of cell surface proteins, in-
cluding immune surveillance (Park et al., 2010; Wilkinson et al.,
2008), signaling (Gredmark et al., 2007; Montag et al., 2011;86 Cell Host & Microbe 12, 86–96, July 19, 2012 ª2012 Elsevier Inc.Popovic et al., 2010), transporter (Yu et al., 2011), and adhesion
proteins (Leis et al., 2004); and RNA array studies predict that
many more surface proteins might be altered (Browne et al.,
2001). However, a comprehensive characterization of HCMV-
induced alterations to the cell surface proteome has not been
reported. Cell surface proteins comprise more than a third of
the human proteome (Josic and Clifton, 2007), they are often
altered on diseased cells and they serve as targets for more
than two-thirds of existing drugs (Overington et al., 2006). There-
fore, it is likely that enhanced understanding of the infected cell
surface proteome will yield insights to viral pathogenesis and
identify previously unexplored targets for treatment of HCMV-
related diseases.
In this study, we compared the cell surface proteome of mock-
infected toHCMV-infected fibroblasts.Mass spectrometry (MS)-
based proteomics identified 505 affinity-enriched proteins at
each time assayed. Using spectral counting analysis, 114 of
these proteins were classified as candidates for differential cell
surface expression after HCMV infection. Two proteins pre-
dicted to increase after infection were the GLUT4 glucose trans-
porter and the LDL receptor-related protein 1 (LRP1). Inhibition
of GLUT4 reduces the yield of virus (Yu et al., 2011), presumably
by blocking HCMV-mediated induction of glycolysis (Munger
et al., 2006; Munger et al., 2008). GLUT4 and LRP1 are delivered
to the plasma membrane together as constituents of insulin-
responsive vesicles and LRP1 can influence GLUT4 expression
(Jedrychowski et al., 2010).
LRP1 (also known as a2-macroglobulin receptor or CD91) is
a ubiquitously expressed, type I transmembrane receptor that
is a member of the low density lipoprotein (LDL)-receptor family
(Herz et al., 1988). It is implicated in numerous physiologic pro-
cesses, including the regulation of lipid metabolism, cell migra-
tion, the proliferation of vascular smooth muscle cells, and neu-
rodevelopment (Franchini and Montagnana, 2011; Lillis et al.,
2008). LRP1 surface expression has been implicated in the
development of atherosclerosis (Boucher and Herz, 2011) and
knockdown of LRP1 results in an increase in intracellular choles-
terol levels in fibroblasts (Terrand et al., 2009; Zhou et al., 2009).
Given the potential for LRP1 to profoundly affect the physi-
ology of HCMV-infected cells, and the possibility that the
receptor and HCMV (So¨derberg-Naucle´r, 2008; Streblow et al.,
2008) might both influence atherogenic lesion development,
we explored the consequences of LRP1 modulation during
HCMV infection. HCMV increased its expression both at the
RNA and protein level. Knockdown of LRP1 increased cellular
and virion cholesterol content, which correlated with increased
Figure 1. Identification of Cell Surface Protein Alterations in HCMV-
Infected Cells
Fibroblasts were mock-infected or infected at a multiplicity of 5 IU/cell.
(A) Specificity of biotin labeling: Avidin-purified cell surface protein prepara-
tions were assayed by western blot for b-actin, insulin receptor (IR), MHC-
class I receptor (HLA-B/C), and prostaglandin receptor 2 (PGE2R2).
(B) Purification of biotinylated proteins: Avidin-purified samples (50 mg
protein in +biotin samples) were subjected to electrophoresis and Coomassie
stained.
(C) Reproducibility of MS data across independent experiments: Normalized
spectral counts of infected cell proteins isolated at 6 (-), 24 (C) and 72 hpi (:)
were were plotted from two independent experiments. Dotted-lines mark
a 2-fold difference in counts.
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RESULTS
Alterations in Cell Surface Protein Abundance after
HCMV Infection
Cell surface proteins regulate many essential cellular processes,
ranging from growth to glucose metabolism, and they also serve
critical roles in cellular defense against invading pathogens. To
monitor alterations to surface proteins during the HCMV replica-
tion cycle, fibroblasts were treated during the immediate-early
(6 hr postinfection, hpi), early (24 hpi), and late (72 hpi) phaseCof infection with an amine-reactive, thiol-cleavable biotin probe,
tagging proteins at the outer surface of the plasma membrane.
Cells were subsequently lysed, and biotin-tagged proteins
were affinity purified using a NeutrAvidin matrix (Figure 1A, left
panel). Samples that were not biotinylated were purified to
monitor non-specific binding to the matrix. Western blot assays
of tagged and purified proteins (Figure 1A, right panel) verified
the presence of plasma membrane-localized insulin receptor,
MHC-class I receptor, and prostaglandin receptor 2 (PGE2R2),
while an abundant intracellular marker, b-actin, was largely
absent. In addition, the analysis confirmed that MHC class I
molecules are downregulated (del et al., 1992) and PGE2R2 is
slightly upregulated (Browne et al., 2001) upon infection, veri-
fying that multiple expression phenotypes were reliably de-
tected. Coomassie staining of avidin-purified proteins in both
HCMV-infected and mock-infected cells demonstrated the effi-
cient isolation of biotin-tagged proteins with limited purification
of proteins in controls that were not biotinylated (Figure 1B).
Cell surface-enriched protein preparations from two indepen-
dent experiments were subjected to MS analysis. To retain
protein identifications that resulted from specific enrichment
via the biotin tag, we utilized label-free spectral counting to eval-
uate protein enrichment in the biotin-labeled versus non-labeled
condition. This method uses the total number of MS/MS spectra
as ameasure of relative protein abundance. In total, 505 proteins
were considered enriched (R5-fold) in biotin-labeled samples
across all conditions, of which 62% have been previously
annotated as cell surface proteins based on Gene Ontology
classification. Since20%of the genome is predicted to encode
plasma membrane proteins, the MS results also support signifi-
cant enrichment of cell surface proteins by this approach.
Further, the portion of avidin-enriched proteins classified as
cell surface residents was similar to that reported for cancer
cell lines (Lund et al., 2009).
To assess temporal, HCMV-dependent regulation of cell
surface proteins, label-free spectral counting was again em-
ployed. Appropriate thresholds for distinguishing significant
HCMV-induced protein abundance changes were selected by
evaluating the spectral count reproducibility between biological
replicates. As shown in Figure 1C, a threshold of R 2-fold
change (minimum 10 spectral counts) resulted in only2% false
positives. Using these criteria, comparison of HCMV- versus
mock-infected samples revealed that 8% of proteins were
altered at 6 hpi, 19% at 24 hpi, and 24% at 72 hpi (Figures
2A–2C). Gene ontology analysis (Mi et al., 2010) grouped the
majority of plasma membrane proteins altered upon infection
into six functional classes: apoptosis (e.g., CD99), cell adhesion
(CSPG4, VCAM1), immune response (CD55, CD59), metabo-
lism (LRP1, GLUT4), transport (Na+2/K-transporting ATPase-
subunits), and signaling (ephrins) (Figure 2D). As illustrated by
hierarchical clustering of altered proteins (Figure 2E), differential
regulation favored upregulation (yellow) at 6 and 24 hpi, while at
72 hpi more proteins were downregulated (blue). In some cases,
proteins were both up and down modulated as infection pro-
gressed (Figure 2E, Table S1), such as vascular cell adhesion
protein 1 (VCAM1) and LRP1. VCAM1 was upregulated at
6 hpi, but downregulated at 72 hpi. This is consistent with
a previous study that showed HCMV infection of endothelial cells
increased cell surface VCAM1, which resulted in an increase inell Host & Microbe 12, 86–96, July 19, 2012 ª2012 Elsevier Inc. 87
Figure 2. Alterations to the Cell Surface Proteome after HCMV
Infection
(A-C) Spectral counts of cell surface proteins: Fibroblasts were mock infected
or infected (5 IU/cell) and analyzed 6 (A), 24 (B) or 72 hr (C) later. Dotted-lines
mark a 2-fold difference in counts.
(D) Differentially expressed proteins grouped by gene ontology analysis.
(E) Heat map showing changes in cell surface protein expression after
infection as compared to mock infection: Proteins upregulated after infection
are yellow, while downregulated proteins are blue. The intensity of the color
reflects the spectral count fold-change. Gene names are listed to the right. The
average change from two independent experiments is displayed for each time
point. Table S1 contains the primary data set underlying this figure.
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sempour et al., 1997). Together, these results indicate that
the composition of the cell surface proteome is diverse and
dynamic, undergoing marked time-dependent changes during
infection.
Experimental Knockdown of LRP1 Generates Virions
with Enhanced Infectivity
MS analysis indicated that LRP1 was transiently elevated at the
cell surface (Figure 2E and Table S1). Given its potential to
profoundly affect the physiology of HCMV-infected cells, LRP1
was chosen for detailed analysis.
Consistent with earlier transcriptome analysis (Browne
et al., 2001), quantification of LRP1 RNA by qRT-PCR showed
that it increased by a factor of 5-10 after infection (Figure 4A,
left), and western blot assays demonstrated that LRP1 protein
was upregulated throughout infection in whole cell lysates
(Figure 3A). In contrast, LRP1 expression on the cell surface
was elevated from 6 to 48 hpi, but not at 72 hpi (Figures
3A and 3B). b-actin (whole cell lysate) and insulin receptor
(plasma membrane) were assayed as loading controls. UV-
inactivated virus also upregulated LRP1 on the cell surface
at 24 hpi (Figure 3B), arguing that virion binding or entry, or
virion constituents are at least partially responsible for LRP1
upregulation. The IE1 protein was assayed as a control to
confirm that the UV-treated virus was unable to express viral
proteins.
Membrane metalloproteinases are activated to cleave LRP1
from the membrane as cellular cholesterol is depleted (Selvais
et al., 2011), generating soluble LRP1 (sLRP1, comprised of
full length LRP1 a chain plus fragments of the a chain). sLRP1
could be immunoprecipitated from the medium at all times after
infection, and its amount increased substantially at 72 hpi (Fig-
ure 3C, top panel). sLRP1 in the medium of infected cells was
able to interact with its ligands (Figure 3C, bottom panel)
because it co-immunoprecipitated with lipoprotein lipase,
a known LRP1 ligand (Boucher and Herz, 2011). GM6001,
a broad-spectrum metalloproteinase inhibitor, reduced the level
of sLRP1 at 72 hpi (Figure 3D), accompanied with a correspond-
ing increase in the level of plasmamembrane LRP1. We interpret
this result to indicate that the reduced level of LRP1 on the cell
surface during the late phase of infection results from its
cleavage and the release of sLRP1 and sLRP1 fragments into
the medium.
To determine the effect of altering LRP1 expression on virus
production, an LRP1-specific siRNA was used to knock down
the protein beginning 24 hr before infection. LRP1 mRNA and
protein were substantially reduced by siRNA treatment at all
times tested after infection (Figures 4A and 4B). Reduced
LRP1 expression increased the production of HCMV infectivity
by a factor of 15 (Figures 4C and D). Experiments included
a mock (no siRNA) and scrambled siRNA as negative controls,
and an IE2 siRNA (an essential viral protein) as a positive control
for protein knockdown resulting in reduced virus replication.
A similar increase in infectivity was obtained by treating infected
cells with a neutralizing antibody for LRP1 (Figure 4E), whereas
no effect was observed using an isotype-specific control.
LRP1 knockdown did not significantly alter the level of viral
DNA or a selected subset of viral mRNAs and proteins compared
Figure 3. Cell Surface LRP1 Is Elevated by HCMV and Released to
the Medium as Infection Progresses
(A) LRP1 is transiently elevated after infection: Whole cell lysates (WCL) and
isolated plasma membrane proteins (PM) were assayed by western blot for
LRP1, b-actin and insulin receptor (IR) at the indicated times after mock
infection or infection (5 IU/cell).
(B) LRP1 is elevated after infectionwith UV-inactivated virus:Whole cell lysates
were assayed by western blot for the viral IE1 protein and isolated plasma
membrane proteins were assayed at the indicated times for LRP1 and IR or at
the indicated times after mock infection or infection (5 IU/cell) with HCMV or
UV-inactivated HCMV (UV HCMV).
(C) Accumulation of soluble LRP1 (sLRP1): At the indicated times after infec-
tion, soluble LRP1 (sLRP1) released into the medium was immunoprecipitated
with LRP1 antibody, captured with protein A beads, then assayed by western
blot for LRP1 (top panel) or lipoprotein lipase (LPL) (bottom panel).
(D) sLRP1 levels in the presence of a metalloproteinase-inhibitor: HCMV
infected cells (5 IU/cell) were treated with GM6001 (10 mM) at 48 hpi, and
LRP1 levels in the medium and at the PM were determined 24 hr later by
western blot.
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not due to increased viral protein or nucleic acid accumulation.
Importantly, however, virion DNA-normalized virus particles
produced in LRP1 knockdown cells were 15-fold more infec-
tious than particles from cells treated with scrambled siRNA (Fig-
ure 4F). Cells receiving the control siRNA produced virions with
a particle to infectious unit ratio of50, within the range of infec-
tivity routinely documented for lab-adapted strains of HCMV
(Mocarski et al., 2007). In contrast, cells receiving LRP1-specific
siRNA generated particles exhibiting a ratio of 3.5. Thus,
reduced LRP1 function does not lead to the production of
more virus particles, but rather generates virions with enhanced
infectivity.CLRP1 Expression Impacts Cellular and Virion
Cholesterol Levels
Since knockdown of LRP1 was shown previously to increase
intracellular cholesterol levels (Zhou et al., 2009), cholesterol is
important for replication of a variety of enveloped viruses
(Pollock et al., 2010), and HCMV infection alters cholesterol
levels (Abrahamsen et al., 1996), the cholesterol content of
LRP1 knockdown cells was examined. As anticipated, when
LRP1 activity was reduced by antibody or siRNA treatment,
intracellular cholesterol levels assayed in extracts of cells lysed
in buffer containing Triton X-100, increased at 24 hr after mock
or HCMV infection (Figure 5A). Similar results were obtained
using an organic solvent to extract cholesterol (Figure S2A). Virus
infection alone resulted in a significant increase in intracellular
cholesterol at 24 hpi. The increase is consistent with earlier
work (Abrahamsen et al., 1996) and occurs in spite of the eleva-
tion of cell surface LRP1, which would favor its decrease.
To characterize the molecular mechanisms triggering the
increase in cholesterol content of LRP1 knockdown cells, we
examined the contribution of de novo cholesterol synthesis to
altered cellular levels. Cells were treated with simvastatin to
block HMG-CoA reductase, the rate limiting step in cholesterol
biosynthesis, and examined its effect on virus release in LRP1-
deficient cells. Simvastatin reduced intracellular cholesterol (Fig-
ure 5B, left) and decreased the release of infectious virus into the
medium in a dose-dependentmanner (Figure 5C); however, it did
not reverse the increase in virus release observed after inhibition
of LRP1 with neutralizing antibody (Figure 5C). In contrast, when
serum starved cells were treated with Simvastatin, the increase
in cholesterol content and infectivity due to LRP1 inhibition
was lost (Figure S2B). Increases in total cellular cholesterol due
to LRP1 inhibition (Figure 5A) could also be negated in choles-
terol-free medium (Figure 5B, right, blue bars), which was
restored by supplementing the medium with LDL-cholesterol
(Figure 5B, right, green bars). Additionally, LDL-cholesterol
supplementation also restored the increase in virus release due
to LRP1 inhibition (Figure 5D). LDL-cholesterol and simvastatin
treatments were not toxic to the cells (Figure S2C). Taken
together, these data demonstrate that increased cholesterol
import, and not de novo synthesis, is largely responsible for
the increase in infectious virus released from LRP1 knockdown
cells.
HCMV Virion Cholesterol Content Affects Infectivity
Increased intracellular cholesterol correlated with elevated virion
infectivity in LRP1 knockdown cells, raising the possibility that
virions released from these cells also have increased cholesterol
content. To investigate this, we quantified the envelope choles-
terol of gradient-purified virus particles from cells with normal
LRP1 function and cells in which LRP1 was inhibited with neu-
tralizing antibody. As predicted, virus released from cells defi-
cient in LRP1 activity (Figure 6A, right panel) exhibited an
increase in virion-associated cholesterol (Figure 6A, left panel).
To more directly explore the role of envelope cholesterol in
HCMV infection, we treated purified virions with methyl-b-cyclo-
dextrin (MbCD), which selectively extracts cholesterol from
membranes (Ohtani et al., 1989). When virus particles released
from LRP1 knockdown cells were treated with 10 mM MbCD
(Figure S3) their cholesterol content and infectivity were reducedell Host & Microbe 12, 86–96, July 19, 2012 ª2012 Elsevier Inc. 89
Figure 4. Inhibition of LRP1 Yields Virions with Enhanced Infectivity
(A) Efficient LRP1 knockdown at the RNA level: Fibroblasts were transfected
with an LRP1-specific siRNA or left untreated. 24 hr later, cells were infected
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is in fact due to increased cholesterol content. Furthermore,
wild-type virions treated with the compound showed a dose-
dependent decrease in cholesterol content, with 90% deple-
tion obtained with 50 mM MbCD (Figure 6B, left). This treatment
resulted in a strikingly similar dose-dependent inhibition of
HCMV infectivity (Figure 6B, right). To assess whether the effect
of MbCD could be rescued and show that the loss of infectivity
was due mainly to cholesterol depletion, exogenous cholesterol
was used to replenish the envelopes of MbCD-treated virions.
This treatment partially restored envelope cholesterol (Figure 6C,
left) and HCMV infectivity (Figure 6C, right), again in a dose-
dependent manner. The highest dose of exogenous cholesterol
tested (2mg/ml) increased the cholesterol content and infectivity
of MbCD-depleted virions by a factor of about 8. Higher choles-
terol doses might completely reverse the depletion, but solubility
issues limited the concentration used in the experiments. Alter-
natively, it is possible that MbCD-treatment also depleted the
virus of another lipid, which would not be replenished by exoge-
nous cholesterol. The infectivity of purified virions containing
a normal level of cholesterol could also be augmented by treating
with exogenous cholesterol. Treatment with 2 mg/ml cholesterol
increased virion cholesterol content by 10% (Figure 6D, left) and
the resulting infectivity by a factor of 2 (Figure 6D, right). In sum,
these results show that depletion of cholesterol from the virion
envelope reduces infectivity and are consistent with the view
that LRP1 modulates the infectivity of virions by controlling their
cholesterol content.
Envelope Cholesterol Content Regulates HCMV Fusion
Infection of host cells by enveloped viruses relies on the fusion
of the viral envelope with either the endosomal or plasma
membrane of the cell. As such, cholesterol might influence the
infectivity of virions by modulating membrane fusion. We tested
this notion by asking if the infectivity of MbCD-treated virions
could be restored by circumventing the normal membrane fusion
process during virus entry. This was done by using low pH to(5 IU/cell); and then, after the indicated time intervals, RNA was isolated and
assayed by real-time qPCR to determine the levels of LRP1 transcripts.
Samples were normalized to GAPDH RNA. Infected cell RNA levels are pre-
sented relative to mock.
(B) Efficient LRP1 knockdown at the protein level: Fibroblasts were transfected
with an LRP1-specific or scrambled control siRNA. 24 hr later, cells were
infected, and, after an additional 24 hr, whole cell lysates were prepared and
assayed by western blot for LRP1.
(C-D) siRNA-mediated LRP1 knockdown produces enhanced yields of infec-
tious HCMV: Fibroblasts were infected (0.1 IU/cell) at 24 hr post transfection
with the indicated siRNAs or no siRNA. 96 hr later, virus in the medium was
assayed by IE1 fluorescence in cultures where nuclei were identified by
Hoechst staining (C) or TCID50 assay (D).
(E) Neutralizing antibody to LRP1 produces enhanced yields of infectious
HCMV. Fibroblasts were infected (0.1 IU/cell) at 1h after treatment with the
indicated antibodies (Ab), and cell-free virus was quantified by a TCID50 assay
96 hr later.
(F) LRP1 knockdown generates virions with enhanced infectivity. Particle to IU
ratios were calculated by dividing the amount of DNA in virus particles by the
virus titer.
Error bars report the standard errors of the means from three experiments,
each performed in triplicate. **p < 0.001 (t test, compared to control condition).
Figure S1 contains additional data relevant to this experiment.
Figure 5. Cholesterol Content Is Increased in LRP1 Knockdown
Cells via Increased Cholesterol Import
(A) Reduced LRP1 activity increases intracellular cholesterol: Fibroblasts were
untreated, transfected with LRP1-specific or scrambled control siRNA for
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Cinduce fusion of the virus envelope with the plasma membrane
(Chang et al., 2010; Mercer and Helenius, 2008; Sun and
Whittaker, 2003). Mock-depleted or cholesterol-depleted parti-
cles were bound to cells at 4C then incubated in a low pH buffer
(pH 4.7) to allow fusion-deficient virus to enter the cell and repli-
cate. A neutral pH buffer was used as a control. Acid bypass of
the fusion event caused a dramatic difference in the ability of
cholesterol-depleted virus to enter the cell and express the IE1
immediate-early protein (Figure 6E). IE1 expression was virtually
undetectable when the cholesterol-depleted particles exposed
to the cell surface in pH 7.4 buffer. In contrast, cholesterol-
depleted particles entered cells and expressed IE1 as efficiently
as mock-depleted particles. We conclude that envelope choles-
terol is a critical determinant of HCMV fusion with the host cell
plasma membrane.
DISCUSSION
The cell surface proteome includes proteins that are physically
embedded in the lipid bilayer, proteins anchored to the outer
leaflet of the plasmamembrane (e.g., glycosylphosphatidylinosi-
tol (GPI)-anchored proteins) and proteins that interact with these
two classes of membrane proteins. We utilized a proteomic ap-
proach, based on the purification membrane-associated protein
ectodomains and MS-based label-free spectral counting anal-
ysis to identify 114HCMV-induced changes (Figure 2E and Table
S1) in proteins predicted to be constituents of the cell surface
proteome (Mi et al., 2010). We identified 28 altered pro-
teins during the immediate-early phase of the replication cycle
(6 hpi); 63 alterations during the early phase (24 hpi) and 83
changes during the late phase (72 hpi). Most of the changes
were not verified by additional methods and thus must be
considered tentative; however, at least 12 of the predicted alter-
ations were reported previously. Platelet derived growth factor
receptors a and b (Gredmark et al., 2007), integrin a-1 (Warren
et al., 1994), epidermal growth factor receptor (Fairley et al.,
2002), and four HLA class I molecules (van der Wal et al., 2002)
were reduced, while CD44 and CD59 adhesion molecules (Ito
et al., 1995), complement decay-accelerating factor (Spiller
et al., 1996), and GLUT4 (Yu et al., 2011) were elevated.24 hr, or treatedwith LRP1 or tubulin antibody for 1 h; and then cells weremock
infected or infected (5 IU/cell). At 24 hpi, cell cholesterol content was
quantified.
(B) Inhibition of cholesterol synthesis had a modest effect, whereas extra-
cellular cholesterol was needed to increase cellular cholesterol after LRP1
inhibition: Cholesterol was quantified after treatment with simvastatin (2.5 mM)
or LDL-cholesterol (50 mg/ml) at 24 hpi.
(C) Inhibition of cholesterol synthesis does not block the enhanced yield of
infectious virus produced by inhibition of LRP1: Fibroblasts were untreated,
treated with simvastatin (2.5 mM), or mock treated; and 30 min later, cells were
treated with antibody to LRP1 or tubulin or left untreated for 1 hr. Cells were
subsequently infected (0.1 IU/cell). At 96 hpi, released virus was quantified by
TCID50 assay. (D) Extracellular cholesterol is required for the enhanced yield of
infectious virus produced by inhibition of LRP1: Cells were serum starved for
48 hr, treated first with the indicated antibodies for 1 hr and then with various
concentrations of LDL-cholesterol for 1 hr. Next, cells were infected (0.1 PFU/
cell) and released virus was assayed by TCID50 assay at 96 hpi.
Error bars report the standard error from three experiments with three repli-
cates each. *p < 0.001 (t test, compared to equivalent control condition).
Figure S2 contains additional data relevant to this experiment.
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Figure 6. Cholesterol Content of Virions Regulates Fusion with the
Plasma Membrane
(A) LRP1 activity correlates with virion cholesterol level: Fibroblasts were left
untreated or transfected with LRP1 siRNA (24 hr before infection) and then
treated with LRP1 neutralizing antibody 24 hr later. After an additional 1 hr,
cells were infected (0.1 IU/cell). Antibody was reapplied every 48 hr. 10 days
later, virus was collected, gradient purified, normalized for virion DNA, and
assayed for cholesterol content. LRP1 plasmamembrane levels were assayed
by western blot to confirm its knockdown.
(B) Depletion of virion cholesterol reduces infectivity: Gradient purified virions
were either mock treated or treated with increasing concentrations of MbCD
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are known membrane glycoproteins, pUL55 (gB), pUL75 (gH),
pUL100 (gM), pUL132 and pRL11, and one, pUL53, forms a
complex with amembrane protein. They were detected predom-
inately late after infection, so they are likely de novo synthesized
rather than delivered by infecting virions.
Cell-coded LRP1 was upregulated at 6 and 24 hpi and down-
regulated at 72 hpi. It regulates cholesterol levels in fibroblasts
(Terrand et al., 2009; Zhou et al., 2009), and changes in intracel-
lular cholesterol flux can influence numerous cell regulatory
processes (Fessler and Parks, 2011). LRP1 upregulates (Zhou
et al., 2009) and HCMV downregulates (Sanchez and Dong,
2010) the ABCA1 transporter beginning at 24 hpi, which pro-
motes the efflux of cholesterol from the cell, and both upregulate
CD36 (Carlquist et al., 2004; Gaultier et al., 2010), which spon-
sors cholesterol import.
Western blot analysis confirmed theMS data showing that cell
surface LRP1 is transiently elevated during infection (Figure 3A),
showing that the changes occur independently of viral gene
expression (Figure 3B), and the decrease in LRP1 late during
infection was shown to result from release of the protein’s ecto-
domain (sLRP1) into themedium (Figure 3C). LRP1was shown to
function as an HCMV restriction factor because abrogation of its
function by siRNA knockdown (Figures 4C and 4D) or antibody
neutralization (Figure 4E) enhanced the yield of HCMV infectivity
by a factor of about 15. The enhanced infectivity was not due to
the production of increased numbers of virions, but rather it re-
sulted from increased specific infectivity (IU/particle) of virons
(Figure 4F). Cellular (Figure 5A) and virion (Figure 6A) cholesterol
content were increased when LRP1 function was inhibited. The
increases depended on the availability of extracellular choles-
terol (Figure 5B), and depletion of cholesterol from virions
reduced their specific infectivity (Figure 6B) and inhibited their
ability to fuse with the plasma membrane at the start of infection
(Figure 6E). The mechanistic role of cholesterol in HCMV-enve-
lope fusion at the plasma membrane during entry remains
unclear, although it is possible that cholesterol is necessary for
the organization of HCMV-virus glycoproteins into fusion-com-
petent domains within the envelope. Depletion of cholesterol
fromHIV-1 (Campbell et al., 2002; Guyader et al., 2002) and influ-
enza virions (Sun and Whittaker, 2003) has also been shown tofor 30 min at 37C. Treated virus was pelleted through a sorbitol cushion to
remove MbCD and infectivity was assayed by IE1 immunofluorescence.
(C) Treatment of cholesterol-depleted virions with exogenous cholesterol
substantially restores infectivity: MbCD-treated (50 mM) virus was incubated
with varying concentrations of cholesterol for 30 min at 37C, pelleted through
a sorbitol cushion, and infectivity was assayed.
(D) Exogenous cholesterol treatment of normal virions enhances infectivity:
Purified virions were incubated in varying concentrations of cholesterol for
30 min at 37C, pelleted through a sorbitol cushion, and infectivity was
assayed.
(E) Cholesterol-depleted virions enter cells efficiently when normal membrane
fusion is bypassed: Fibroblasts were infected (3 IU/cell) with MbCD-treated
(50 mM) or mock-treated virus, allowed to sit at 4C for 30 min to allow virus
binding, then treated with buffer at neutral (7.4) or acidic (4.7) pH for 3 min.
Cells were assayed for IE1 expression at 24 hpi. Error bars for all panels
report the standard error from three experiments with three replicates each.
*p < 0.001 (t test, compared to control condition). Figure S3 contains additional
data relevant to this experiment.
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infection.
It is noteworthy that HCMV infection elevated cellular choles-
terol by a factor of about three at 24 hpi (Figure 5A), in spite of the
fact that LRP1 was increased at the plasma membrane from
6-48 hpi (Figures 2E and 3A; Table S1). The increase in total
cell cholesterol following infection could result from HCMV-
mediated downregulation of the ABCA1 transporter (Sanchez
and Dong, 2010). Importantly, when LRP1 function was inhibited
by treatment with siRNA or neutralizing antibody, the level of
infected cell cholesterol increased at 24 hpi (Figure 5A), demon-
strating that LRP1 is limiting the virus-induced increase in cellular
cholesterol.
As the infection enters the late stage (72 hpi and later, Fig-
ure 3A), the level of LRP1 is reduced. The reduction results
from the cleavage and release of sLRP1 from the cell surface
late during infection with a cellular membrane metalloproteinase
(Figure 3C); however, we do not yet know which metalloprotei-
nase triggers the cleavage. The release might be induced by
a late viral gene product that activates a metalloproteinase
responsible for the cleavage. Cholesterol has been shown to
control LRP1 levels at the plasma membrane by modulating
membrane-type 1 matrix metalloproteinase and metalloprotei-
nase-12 activity (Selvais et al., 2011). Whatever the mechanism,
reduced LRP1 levels would be expected to increase intracellular
cholesterol levels and promote the production of virions with
enhanced infectivity. It is possible that sLRP1 competes for
ligand binding within the microenvironment of the residual cell-
associated LRP1, further reducing its function at the plasma
membrane. The soluble protein also might compete with and
reduce LRP1 function in nearby uninfected cells, preparing
them for infection.
In summary, our results demonstrate that the HCMV-infected
cell surface proteome is markedly dynamic in its composition,
with a substantial portion of the proteins that we have monitored
increasing or decreasing at various times during the virus re-
plication cycle. LRP1 provides an example of this dynamic
behavior, and our analysis demonstrates that it functions as an
HCMV restriction factor during the early stages of infection (until
at least 48 hpi, Figure 3A). LRP1 limits the availability of choles-
terol and, as a consequence, reduces the infectivity of newly
produced virions. LRP1 also has been shown to be elevated in
HIV-1-infected T cells (Rasheed et al., 2008) and in monocytes
of HIV-1-infected individuals whose disease doesn’t progress




Human MRC5 fibroblasts (ATCC) were cultured in Dulbecco-modified Eagle
medium (DMEM) containing 10% fetal bovine serum. Cell viability was
assessed by a trypan blue exclusion assay (Moorman et al., 2010). HCMV
was prepared from a bacterial artificial chromosome (BAC) clone of the
AD169 strain expressing GFP (BADinGFP) (Wang et al., 2004). Virus stocks
were concentrated and partially purified by centrifugation through 20%
sorbitol cushions, and in some cases further purified in sodium tartrate gradi-
ents (Irmiere and Gibson, 1983).
Virus titers (infectious units, IUs) were determined by tissue culture in-
fectious dose (TCID50) assay or by quantifying infected fibroblasts using
IE1-specific antibody (clone 1B-12) (Zhu et al., 1995). Fluorescent imagesCwere processed with Q-Capture Pro software (Luo et al., 2007). Error bars
represent the standard errors of the means from two or three independent
experiments, each performed in triplicate. Virion infectivity was determined
by measuring IUs and viral DNA in virions (Womack and Shenk, 2010).
Isolation of Cell Surface Proteins
Confluent fibroblasts were mock infected or infected with HCMV (5 IU/cell).
After 6, 24, or 72 hr, plasmamembrane proteins were isolated using the Pierce
cell surface protein isolation kit. In brief, surface proteins were tagged with
a thiol-cleavable biotin moiety, sulfo-NHS-SS-biotin [sulfosuccinimidyl-2-
(biotinamido)ethyl-1,3-dithiopropionate], which contains a 24.3 A˚ spacer arm
and reacts with the epsilon-amine of lysine residues, lysed in detergents
(0.1%SDS, 1.0%Triton-X, 1.0% sodium deoxycholate) and sonicated. Biotiny-
lated proteins were bound to a NeutrAvidin matrix (Pierce), and labeled
proteins were eluted in buffer containing dithiothreitol [50 mM]. MS studies
used one 15 cm plate and western blot assays one 3.5 cm plate of fibroblasts
per sample.
Mass Spectrometry
Filter-aided sample preparation (FASP) (Wisniewski et al., 2009) was used to
generate tryspinized proteins for MS. About 1/4 of the 250 mg total protein
recovered from the NeutrAvidin matrix wasmixed with 400 ml of 0.1M Tris-HCl,
pH 8.0, containing 8 M urea (UB) in a YM-10 Microcon device (Millipore).
Samples were concentrated at 14,000 x g, then washed with 400 ml of UB.
Following centrifugation, 200 ml of UB containing 0.05 M iodoacetamide was
added. Samples were mixed on a TOMY shaker for 1 min then incubated at
room temperature in the dark for 30 min. Following centrifugation, 200 ml of
0.05 M ammonium bicarbonate (ABC) was added to the filter unit and concen-
trated. This step was repeated twice. The concentrate was subjected to
proteolytic digestion overnight at 37C in 100 ml of 0.05 M ABC containing
10 ng/ml trypsin (Promega). The peptide digests were collected by centrifuga-
tion, and the filter was rinsed with 3 3 50 ml of HPLC grade water and cen-
trifuged. Samples were acidified to a final concentration of 1% trifluoroacetic
acid. Vacuum centrifugation was used to concentrate the sample to0.5 mg/ml
prior to MS analysis.
Tryptic peptides (2.5 mg) were analyzed (Tsai et al., 2012) by nLC-MS/MS
on a Dionex Ultimate 3000 RSLC coupled directly to an LTQ-Orbitrap Velos
ETD mass spectrometer (ThermoFisher Scientific) operated in data-depen-
dent acquisition mode with FT preview scan disabled and predictive AGC
and dynamic exclusion enabled (repeat count: 1, exclusion duration: 90 s).
A single acquisition cycle comprised a single full-scan mass spectrum
(m/z = 350 – 1700) in the orbitrap (R = 30,000 @ m/z = 400), followed by CID
fragmentation in the linear ion trap on the top 20 most intense precursor
ions (min. signal = 1000) determined from the full-scan mass spectrum.
MS/MS spectra from raw data files were extracted by Proteome Discover
(ver. 1.3, ThermoFisher Scientific) and submitted to SEQUEST (ver. 1.20) to
search against the UniProt SwissProt sequence database (downloaded 11/
2010) containing the subset of human, herpesvirus, and common contaminant
sequences (21,570 entries). Peptide spectrum matches (PSMs) were gener-
ated by searching MS/MS spectra against indexed peptide databases, gener-
ated from the forward and reverse protein sequence entries (Tsai et al., 2012).
Q-values for SEQUEST PSMs were calculated using the Percolator algorithm
(Spivak et al., 2009) and filtered to achieve a global peptide false discovery rate
of % 1%. Filtered peptide assignments were assembled into protein groups
with a minimum of two unique peptides per protein using strict rules of
parsimony.
For spectral counting analyses, total assigned spectra for each protein
group (including unique and shared sequences) were used. After normalizing
each sample set for total spectral counts, proteins with a count below 10
were removed. Specificity of enrichment was calculated for each protein as
the spectral count ratio of biotinylated/non-biotinylated. Proteins with less
than 5-fold enrichment were removed. HCMV-induced protein alterations
were similarly calculated for each protein as the spectral count ratio of
infected/uninfected. A change ofR 2.0-fold in spectral count ratio was consid-
ered differentially regulated since comparison of spectral counts between bio-
logical replicates resulted in 98% of proteins that were changed % 2-fold
(Figure 1C). Subcellular protein localization was obtained using Proteome
Discoverer (ver. 1.3, ThermoFisher Scientific).ell Host & Microbe 12, 86–96, July 19, 2012 ª2012 Elsevier Inc. 93
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To reduce the level of LRP1 protein, siRNA (50-CAUCGAUCUUCACAAA
GGA-30) was transfected into fibroblasts at about 80% confluency using
opti-mem and oligofectamine (Invitrogen). To inhibit LRP1 with neutralizing
antibody, fibroblasts were grown to 100% confluency and incubated at
37C with 15 mg/ml LRP1 neutralizing antibody (Progen) (Orr et al., 2003). To
assay the effect of inhibition, fibroblasts were infected (0.1 IU/cell) at 24 hr
post siRNA transfection or 60 min after antibody treatment, and infectious
progeny was assayed 96 hr later.
Analysis of Nucleic Acids and Proteins
Viral DNA and RNA was assayed by qPCR or qRT-PCR, respectively, and
proteins were monitored by western blot assay (Womack and Shenk, 2010).
Antibodies to the following antigens were used: LRP1 and a-tubulin (Sigma);
LDLR, ABCA1, LPL, Insulin Receptor, PGE2R2 and b-actin-HRP (Abcam);
HLA-B/C (Santa Cruz); (ICP36)UL144 (Virusys); (pUL123)IE1 (clone 1B-12)
(Zhu et al., 1995), (pp28)UL99 (clone 10B4-29) (Silva et al., 2003). To assay
cell-free sLRP1, medium was concentrated, sLRP1 was immunoprecipitated
using specific antibody or isotype control (R&D systems), and proteins were
analyzed by western blot.
Manipulation and Quantification of Cholesterol Levels
To inhibit cholesterol synthesis, fibroblasts were incubated for 90 min prior to
infection or mock infection with simvastatin (1.5 or 2.5 mM; Sigma). To inhibit
LDLR-mediated cholesterol import, cells were transfected with siRNA (50-GUC
UUUGAGGACAAAGUAU-30) 24 hr prior to infection or mock infection.
For treatment of cells with cholesterol, serum-starved (48 h), confluent fibro-
blasts received various concentrations of cholesterol + fatty acid-free (>96%)
BSA (Sigma) for 1 hr before mock infection or infection.
For treatment of virions with cholesterol, purified particles (107 IU in 50 ml)
were incubated in various concentrations of exogenous cholesterol (Sigma) for
30 min at 37C. Immediately after treatment, virions were centrifuged through
a sorbitol cushion to remove exogenous cholesterol, and used to infect fibro-
blasts (0.5 IU/cell). Virus cholesterol content was determined using the Amplex
Red Cholesterol Assay (Invitrogen).
To deplete cholesterol from virions, purified particles (107 IU in 50 ml)
were mock treated (PBS only) or treated with increasing concentrations of
methyl-b-cyclodextrin (MbCD) (Sigma) for 30 min at 37C (Ohtani et al.,
1989; Sun and Whittaker, 2003). Immediately after treatment, virions were
centrifuged through a sorbitol cushion, and used to infect fibroblasts. For
rescue experiments, exogenous cholesterol (Sigma) was added to the virion
cyclodextrin mixture at 37C for 30 min, before centrifugation through
a sorbitol cushion.
To quantify cholesterol levels, cells or virions were lysed in PBS containing
1% Triton X-100 and protease inhibitor cocktail (Sigma). Cell lysates were
clarified by centrifugation, and cholesterol content was determined using the
Amplex Red Cholesterol Assay (Invitrogen). When cells were extracted with
an organic solvent [chloroform:isopropanol:NP-40 (7:11:0.1)], the Abcam
cholesterol quantification kit was used. Cellular and viral cholesterol content
were normalized to cell number and viral DNA, respectively.
Acid Bypass Assay
After addition of virus, cells were maintained at 4C for 30 min to allow virus
binding, then treated with buffer at a neutral (Tris, pH 7.4) or acidic (MES,
pH 4.7) pH for 3 min (Chang et al., 2010), washed with PBS, and examined
for IE1 expression at 24 hpi.
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